Navigation Links
Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
Date:1/31/2008

COLUMBIA, Md., Jan. 31 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK), a DHA omega-3 market leader, announced today that leading DHA researcher and expert Dr. Norman Salem, Jr., will be joining Martek Biosciences on February 4, 2008, as vice president and chief scientific officer.

Dr. Salem is one of the world's leading researchers on DHA and the functions of polyunsaturated fatty acids and lipids. He comes to Martek after 30 years with The National Institutes of Health where he led the internationally recognized Laboratory of Membrane Biochemistry and Biophysics. His latest scientific work focused on the role of DHA in neural development as well as how DHA is made in the body and incorporated into the brain and other organs.

As Martek's chief scientific officer, Dr. Salem will be responsible for leading clinical research, discovery, microbial biotechnology, and analytical sciences and will support the efforts of scientific affairs and medical research.

Dr. Salem received his B.S. degree in physics from Miami University and his Ph.D. in neurobiology from the University Of Rochester School Of Medicine. During his career, Dr. Salem has published over 200 research articles and book chapters. He was the 2002 recipient of the Supelco/Nicholas Pelick Research Award from the American Oil Chemists Society, which recognizes outstanding original research in fats, oils, lipid chemistry, or biochemistry. He currently serves as a research professor in the Department of Pediatrics at the F. Edward Hebert School of Medicine of Uniformed Services University of the Health Sciences.

"We are pleased to welcome Dr. Salem, a prominent expert on the science of DHA, to Martek. His scientific knowledge and experience in DHA research will provide Martek with important senior-level leadership for our clinical, scientific and research areas," said Steve Dubin, CEO of Martek Biosciences.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit http://www.martek.com. For a complete listing of life'sDHA products, visit http://www.lifesdha.com.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2007 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Contact:

Cassie France-Kelly

Consumer and Trade Media

Martek Biosciences

(443) 542-2116

media@martek.com

Kyle Stults

Investor Relations

Martek Biosciences

(410) 740-0081

investors@martek.com


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
2. Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack
3. Masada Teams With Leading Waste Management Firm to Produce Ethanol From Municipal Solid Waste in the Dominican Republic
4. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
5. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
6. Germany Hosts World Leading Medical Industry Fair
7. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
8. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
9. Leading Edge Research Underway in Fall Prevention for Seniors
10. Cognizant to Acquire marketRx, a Leading Provider of Life Sciences Market Analytics
11. 2007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic ... Symposium. Using molecular test results from tumors with previously documented positive, negative, ...
(Date:12/2/2016)... ... December 01, 2016 , ... PhUSE will build ... popularity of US Single Day Events (SDE) to organize a multiple-day US conference. ... Raleigh, NC. Topics of the pharmaceutical and life sciences industry will cover industry ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only ... a beautiful technology experience. All three tenets were on display at the 2nd Annual ... from over 40 sponsor, CRO and site organizations to discuss innovation and the future ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved chemistry, ... in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
Breaking Biology Technology:
(Date:11/22/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the company has been ... Awards as "Most Outstanding in eClinical Solutions" for ... recognition and growth for MedNet, which has effectively supported ... iMedNet ™ , MedNet,s flagship eClinical technology ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):